Keyphrases
Direct Oral Anticoagulants
100%
Neuroblastoma
68%
Rivaroxaban
47%
Apixaban
47%
Neuroblastoma Cells
47%
Tumorigenic Effects
41%
PDGFRB Fusion
41%
CCDC88C
41%
Sternness
41%
Lymphoblastic Lymphoma
41%
Klotho Protein
41%
Cannabidiol
41%
In Vivo Efficacy
41%
2-Hydroxyoleic Acid
41%
Anandamide
41%
Endocannabinoids
41%
Fracture Management
41%
Fracture Liaison Service
41%
Levetiracetam
41%
Stewardship Program
41%
Management Strategy
41%
Clinical Pharmacist
41%
Pharmacist-led
41%
Peak Plasma Concentration
41%
Enzyme Inducer
41%
Oral Drugs
41%
Drug-metabolizing Enzymes
41%
Enzyme-inducing Anti-seizure Medication
41%
Oleic Acid
27%
Senolytics
27%
Pharmacology, Toxicology and Pharmaceutical Science
Direct Oral Anticoagulant
100%
Glioblastoma
82%
Neuroblastoma
82%
Rivaroxaban
47%
Apixaban
47%
Tetrahydrocannabinol
47%
Cannabidiol
41%
Temozolomide
41%
Ricinoleic Acid
41%
Carcinogenesis
41%
Cytotoxicity
41%
Anandamide
41%
Endocannabinoid
41%
Dronabinol
41%
Klotho Protein
41%
Hip Fracture
41%
Anticoagulant Agent
41%
Levetiracetam
41%
Fragility Fracture
41%
Drug Metabolizing Enzyme
41%
Combination Therapy
34%
Cannabinoid
30%
Neoplasm
22%
Malignant Neoplasm
22%
Caspase 3
20%
Cyclin A
20%
Oleic Acid
20%
Diseases
20%
Vitamin D
20%
Cannabinoid
17%
Biochemistry, Genetics and Molecular Biology
Mutated Genes
51%
Tetrahydrocannabinol
41%
Platelet Derived Growth Factor Receptor Beta
41%
Carcinogenesis
41%
Synapsin I
41%
Downregulation
41%
Ataxia Telangiectasia Mutated
41%
Anandamide
41%
Methylation
41%
E2F1
41%
Hematopoietic Cell
41%
CD133
41%
Cell Cycle Progression
41%
Enzyme
41%
Enzyme Inducer
41%
Cannabinoid
38%
Oleic Acid
27%
Missense Mutation
20%
Cyclin A
16%
Cell Cycle
16%
Cell Growth
14%
Antiproliferative Activity
13%
Galactosidase
13%
Caspase 3
13%
Promoter Region
13%
Anticancer
13%
Messenger RNA
12%
Phosphotransferase
10%
Kinase
10%
Splice Site Mutation
10%